|
10008
|
PiCoVacc
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Sinovac Biotech Ltd.
|
2020
|
China
|
18 - 59 years
|
2 doses 14 or 28 days apart
|
Intramuscular
|
Aluminum (alum)
|
NA
|
NA
|
WHO
|
NA
|
Brazil, Indonesia, Turkey
|
CoronaVac
|
32328406
|
NA
|
https://pubmed.ncbi.nlm.nih.gov/32328406/
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202686/
|
|
10009
|
Sinopharm Vaccine (Vero cell inactivated)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Sinopharm
|
2020
|
China
|
NA
|
2 doses 14 or 21 days apart
|
Intramuscular
|
Aluminum (alum)
|
NA
|
NA
|
WHO
|
NA
|
Jordan, Bahrain, Morocco, UAE
|
NA
|
32328406
|
NA
|
https://pubmed.ncbi.nlm.nih.gov/32328406/
|
https://covid19.health.gov.mv/wp-content/uploads/2021/10/SINOPHARM-INFORMATION-SHEET_Final-Revised-09th-June.pdf
|
|
10010
|
BBIBP-CorV (Vero cell) (Covilo)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
China National Biotec Group Company Limited
|
2021
|
China
|
18 years and above
|
2 doses 14 or 28 days apart
|
Intramuscular
|
Aluminum
|
NA
|
NA
|
WHO
|
Beijing Institute of Biotechnology
|
UAE, Jordan, Egypt, Bahrain, Argentina
|
BBIBP-CorV, COVILO
|
32328406
|
NA
|
https://pubmed.ncbi.nlm.nih.gov/32328406/
|
https://www.precisionvaccinations.com/vaccines/sinopharm-covid-19-vaccine-bbibp-corv
|
|
10081
|
Flublok Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Sanofi Pasteur
|
2013
|
NA
|
18 years and above
|
Single dose
|
Intramuscular
|
NA
|
Hemagglutinin
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10082
|
FluMist Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
AstraZeneca plc
|
2003
|
Canada
|
2 - 49 years
|
Single dose
|
Intranasal
|
NA
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
Tamiflu, Relenza
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10084
|
ERVEBO
|
Ebola
|
Hemorrhagic
|
Zaire ebolavirus
|
negative-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Merck & Co. Inc.
|
2019
|
USA
|
18 years and above
|
Single dose
|
Intramuscular
|
NA
|
Zaire Ebola virus glycoprotein
|
NA
|
US FDA, EMA
|
NA
|
NA
|
V920, rVSV-G-ZEBOV-GP, rVSV-ZEBOV
|
NA
|
NA
|
https://www.cdc.gov/vhf/ebola/clinicians/vaccine/index.html
|
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2817%2930313-4/fulltext
|
|
10086
|
YF-Vax
|
Yellow fever
|
Hemorrhagic
|
Yellow fever virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Sanofi Pasteur
|
NA
|
France
|
9 months and above
|
Single dose
|
Subcutaneous
|
NA
|
17D-204 strain of yellow fever virus
|
Culturing 17D-204 strain of yellow fever virus in living avian leukosis virus-free (ALV-free) chicken embryos
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/media/76015/download
|
https://www.fda.gov/media/76015/download
|
|
10087
|
CYD-TDV Dengvaxia
|
Dengue fever
|
Hemorrhagic
|
Dengue virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Sanofi Pasteur
|
2015
|
France
|
9 - 45 years
|
3 doses 6 months apart
|
Subcutaneous
|
NA
|
Dengue virus serotypes (1, 2, 3 and 4)
|
17D vaccine vector expressing genes of DENV-1, 2, 3, or 4
|
US FDA
|
NA
|
NA
|
NA
|
30684747
|
NCT02747927
|
https://www.sciencedirect.com/science/article/pii/S1201971219300402
|
https://www.fda.gov/media/124379/download
|
|
10088
|
Weisairuiji Biovac-A Mevac-A
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Biogenetech Co. Ltd., Zhejiang Pukang Biotechnology Co. Ltd.
|
2010
|
Thailand
|
1.5 years and above
|
Single dose
|
Subcutaneous
|
NA
|
H2 strain of HAV
|
H2-attenuated strain of HAV cultured in human diploid cells.
|
China FDA, US FDA
|
NA
|
NA
|
MEVAC-A
|
24280971
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130259/
|
https://apps.who.int/iris/bitstream/handle/10665/326501/97892516327-eng.pdf
|
|
10089
|
Weisairuiji Biovac-A Mevac-A
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Institute of Medical Biology, Chinese Academy of Medical Sciences
|
NA
|
China
|
NA
|
Single dose
|
Subcutaneous
|
NA
|
H2 strain of HAV
|
NA
|
China FDA, US FDA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.fda.moph.go.th/sites/drug/Shared%20Documents/Vaccine/U1DR1C1072530000811C-SPC.pdf
|
|
10090
|
HAVAC
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Changchun Institute of Biological Products
|
NA
|
China
|
NA
|
Single dose
|
Subcutaneous
|
NA
|
LA-1
|
NA
|
Government of Canada
|
Changchun Changsheng Life Sciences
|
NA
|
NA
|
24280971
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130259/
|
https://www.canada.ca/en/public-health/services/publications/healthy-living/update-recommended-use-hepatitis-b-vaccine.html
|
|
10091
|
HAVAC
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Changchun Institute of Biological Products
|
NA
|
China
|
NA
|
Single dose
|
Subcutaneous
|
NA
|
LA-1
|
NA
|
Government of Canada
|
Changchun Changsheng Life Sciences
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.canada.ca/en/public-health/services/publications/healthy-living/update-recommended-use-hepatitis-b-vaccine.html
|
|
10121
|
KAMRAB-003
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Kamada Ltd.
|
2014
|
USA
|
18 - 75 years
|
5 doses on day 0, 3, 7, 14 and 28
|
Intramuscular
|
NA
|
NA
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NCT02040090
|
https://clinicaltrials.gov/ct2/show/NCT02040090?cond=Rabies+Human&phase=23&draw=2&rank=5
|
https://pdf.hres.ca/dpd_pm/00048173.PDF
|
|
10123
|
SA14-14-2 (IXIARO)
|
Viral encephalitis
|
Neurologic
|
West Nile virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Sanofi Pasteur
|
2013
|
Thailand
|
NA
|
NA
|
Subcutaneous
|
NA
|
SA 14-14-2
|
Cell culture based
|
NA
|
NA
|
NA
|
NA
|
24161909
|
NCT01092507
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185882/
|
https://www.fda.gov/media/75777/download
|
|
10126
|
IMOJEV
|
Viral encephalitis
|
Neurologic
|
West Nile virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Sanofi Pasteur
|
2017
|
Thailand
|
9 months and above
|
3 doses
|
Subcutaneous
|
NA
|
SA 14-14-2
|
Mouse brain based
|
US FDA
|
NA
|
NA
|
ChimeriVax-JE, JE-CV, THAIJEV (Sanofi-Aventis)
|
24161909
|
NCT01900444
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185882/
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/japanese-encephalitis-vaccine-inactivated-adsorbed
|
|
10131
|
ACAM2000
|
Smallpox
|
Exanthous
|
Variola virus
|
double stranded DNA
|
Live-attenuated
|
Approved
|
Emergent BioSolutions
|
2003
|
USA
|
Below 12 months of age
|
Single dose
|
Percutaneous
|
NA
|
Recombinant vaccinia viruses derived from replication-competent vaccinia strain
|
Lyophilized
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/acam2000
|
NA
|
|
10132
|
JYNNEOS
|
Smallpox
|
Exanthous
|
Variola virus
|
double stranded DNA
|
Live-attenuated
|
Approved
|
Bavarian Nordic
|
NA
|
Denmark
|
18 years and above
|
2 doses 4 weeks apart
|
Subcutaneous
|
NA
|
Vaccinia Virus Ankar
|
NA
|
US FDA
|
NA
|
NA
|
Imvamune, Imvanex, MVA-BN
|
NA
|
NA
|
https://www.fda.gov/vaccines-blood-biologics/jynneos
|
https://www.fda.gov/media/131078/download
|
|
10133
|
Aventis Pasteur Smallpox Vaccine
|
Smallpox
|
Exanthous
|
Variola virus
|
double stranded DNA
|
Live-attenuated
|
Approved
|
National Institute of Allergy and Infectious Diseases
|
2010
|
USA
|
18 - 32 years
|
NA
|
Percutaneous
|
NA
|
NA
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NCT00038987
|
https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/smallpox-preparedness-and-response-updates-fda
|
https://clinicaltrials.gov/ct2/show/NCT00038987
|
|
10134
|
Priorix
|
Measles, Mumps, Rubella, Chickenpox
|
Exanthous
|
Morbillivirus, Mumps virus, Rubella virus, Varicella-zoster virus
|
negative-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
GlaxoSmithKline
|
2019
|
NA
|
11 months - 22 months
|
2 doses 42 days apart
|
Subcutaneous
|
NA
|
Vaccinia Virus
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT00226499
|
https://www.fda.gov/vaccines-blood-biologics/priorix
|
https://clinicaltrials.gov/ct2/show/NCT00226499
|
|
10135
|
Varivax
|
Chickenpox
|
Exanthous
|
Varicella-zoster virus
|
double stranded DNA
|
Live-attenuated
|
Approved
|
Merck & Co. Inc.
|
2007
|
USA
|
1 - 12 years
|
2 doses (0.5 ml each) separated by at least 3 months.# First dose: age 12 through 15 months, Second dose: age 4 through 6 years
|
Subcutaneous
|
NA
|
Oka/Merck strain of live-attenuated varicella virus
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NCT00822237
|
https://www.cdc.gov/vaccines/vpd/varicella/index.html
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/varivax
|
|
10136
|
Varivax
|
Chickenpox
|
Exanthous
|
Varicella-zoster virus
|
double stranded DNA
|
Live-attenuated
|
Approved
|
Merck & Co. Inc.
|
2007
|
USA
|
12 - 23 months
|
2 doses 4 weeks apart
|
Subcutaneous
|
NA
|
Oka/Merck strain of live-attenuated varicella virus
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/varicella/index.html
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/varivax
|
|
10137
|
ProQuad
|
Measles, Mumps, Rubella, Varicella
|
Exanthous
|
Morbillivirus, Mumps virus, Rubella virus, Varicella-zoster virus
|
negative-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Merck & Co. Inc.
|
NA
|
USA
|
1 - 12 years
|
First dose at 12 through 15 months of age and Second dose at 4 through 6 years of age
|
Subcutaneous
|
NA
|
NA
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NCT00985166
|
https://www.cdc.gov/vaccines/vpd/varicella/index.html
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/proquad
|
|
10138
|
RotaTeq (RV5)
|
Rotavirus Infection
|
Gastrointestinal
|
Rotavirus
|
double stranded RNA
|
Live-attenuated
|
Approved
|
Merck & Co. Inc.
|
NA
|
USA
|
6 months - 8 months
|
3 doses at age of 2 months, 4 months, and 6 months
|
Oral
|
NA
|
5 human-bovine reassortant rotaviruses (G1, G2, G3 G4, P[8])
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/rotavirus/index.html
|
https://www.fda.gov/media/75718/download
|
|
10139
|
Rotarix (RV1)
|
Rotavirus Infection
|
Gastrointestinal
|
Rotavirus
|
double stranded RNA
|
Live-attenuated
|
Approved
|
GlaxoSmithKline
|
2006
|
UK
|
6 months - 8 months
|
2 doses at ages 2 months and 4 months
|
Oral
|
NA
|
Human rotavirus strain (G1P[8])
|
NA
|
US FDA, EMA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/rotavirus/index.html
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/rotarix
|
|
10140
|
Rotavac
|
Rotavirus Infection
|
Gastrointestinal
|
Rotavirus
|
double stranded RNA
|
Live-attenuated
|
Approved
|
Bharat Biotech International Limited
|
2013
|
India
|
6 months - 8 months
|
3 doses 4 weeks apart
|
Oral
|
NA
|
Rotavirus 116E strain
|
NA
|
US FDA, Government of India
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.who.int/immunization/research/meetings_workshops/11_Cassels_Rotavirus_PDVAC_2019.pdf?ua=1
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/rotavirus-vaccine-live-oral
|
|
10141
|
RotaSiil
|
Rotavirus Infection
|
Gastrointestinal
|
Rotavirus
|
double stranded RNA
|
Live-attenuated
|
Approved
|
Serum Institute of India
|
2017
|
India
|
6 months - 8 months
|
3 doses 4 weeks apart
|
Oral
|
NA
|
Human-bovine reassortant rotaviruses (G1, G2, G3, G4, G9)
|
NA
|
National Institute of Health, Government of India
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.who.int/immunization/research/meetings_workshops/11_Cassels_Rotavirus_PDVAC_2019.pdf?ua=1
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/rotarix
|
|
10142
|
BL 125296
|
Adenovirus Infection
|
Respiratory
|
Adenovirus Type 4, Type 7
|
double stranded DNA
|
Live-attenuated
|
Approved
|
Barr Pharmaceuticals Inc.
|
NA
|
USA
|
17 - 50 years
|
2 doses
|
Oral
|
NA
|
Live adenovirus
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/media/80211/download
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/adenovirus-type-4-and-type-7-vaccine-live-oral
|
|
10162
|
COVI-VAC
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
Codagenix Inc.
|
2021
|
UK
|
18 - 30 years
|
2 doses 28 days apart
|
Intranasal
|
NA
|
SARS CoV 2 whole virus
|
NA
|
NA
|
Serum Institute of India
|
NA
|
CDX-005
|
33816047
|
NCT04619628
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/
|
NA
|
|
10175
|
MV-014-212
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
Meissa Vaccines Inc.
|
2021
|
USA
|
18 - 69 years
|
2 doses 35 days apart
|
Intranasal
|
NA
|
Spike protein of SARS-CoV-2 virus
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT04798001
|
https://clinicaltrials.gov/ct2/show/NCT04798001?term=covid-19+vaccine&draw=2
|
NA
|
|
10211
|
rDEN3delta30/31-7164
|
Dengue fever
|
Hemorrhagic
|
Dengue virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
National Institute of Allergy and Infectious Diseases
|
2013
|
USA
|
18 - 50 years
|
NA
|
Subcutaneous
|
NA
|
Dengue virus serotypes -3
|
NA
|
NA
|
Johns Hopkins Bloomberg School of Public Health
|
NA
|
NA
|
NA
|
NCT00831012
|
https://clinicaltrials.gov/ct2/show/NCT00831012?recrs=abde&cond=dengue+fever&phase=0123&draw=2&rank=12
|
NA
|
|
10212
|
MV-LASV (V182-001)
|
Lassa fever
|
Hemorrhagic
|
Lassa virus
|
negative-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
Themis Bioscience
|
2021
|
Belgium
|
18 - 55 years
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
Measles Schwarz virus strain for prophylaxis of Lassa infection
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT04055454
|
https://clinicaltrials.gov/ct2/show/NCT04055454?cond=Lassa+fever&draw=2&rank=10
|
NA
|
|
10214
|
RH-CHIKV EV-CHIKV RHEV-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
Footpad injection
|
NA
|
R532H-nsP, E515V-nsP2
|
NA
|
NA
|
NA
|
NA
|
NA
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10215
|
Delta 5nsP3 DREP-E MVA-CE
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
Subcutaneous
|
NA
|
CHIKV nsP3 envelope and capsid protein
|
NA
|
NA
|
NA
|
NA
|
NA
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10223
|
USAMRIID
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
NA
|
NA
|
NA
|
NA
|
1- 2 doses depending on volume and age
|
NA
|
NA
|
NA
|
Formalin inactivated produced in green monkey kidney cells or chick embryonic cells
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10225
|
Measles-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
NA
|
NA
|
CHIKV proteins
|
Recombinant measles virus (Schwartz strain) expressing CHIKV VLPs
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10226
|
TSI-GSD-218
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10227
|
CHIKV Delta 5nsP3
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
Clinical strain attenuated by targeted mutations in nsP3, 6 K
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10233
|
IRES-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
University of Texas Medical Branch, Takeda Pharmaceutical Company Limited
|
2011
|
USA
|
NA
|
NA
|
Subcutaneous
|
NA
|
La Reunion strain
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3145802/
|
|
10298
|
CHIKV-NoLS
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 2
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
Subcutaneous
|
NA
|
N-terminal region of capsid protein
|
NA
|
NA
|
NA
|
NA
|
NA
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10303
|
MV-CHIK
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 2
|
Themis Bioscience
|
2021
|
USA
|
21 - 65 years
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
US FDA
|
Walter Reed Army Institute of Research
|
NA
|
NA
|
NA
|
NCT03807843
|
https://clinicaltrials.gov/ct2/show/NCT03807843
|
NA
|
|
10304
|
TSI-GSD-218
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 2
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
NA
|
NA
|
NA
|
Attenuation by serial, plaque-to-plaque MRC5 cell passages
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10307
|
MV-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 2
|
Institut Pasteur of Shanghai, Themis Bioscience
|
2021
|
NA
|
18 - 55 years
|
3 doses on day 0, 28 and 196
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT02861586
|
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919
|
https://clinicaltrials.gov/ct2/show/NCT02861586
|
|
10309
|
MeMuRu-OKA
|
Measles, Mumps, Rubella, Varicella
|
Exanthous
|
Morbillivirus, Mumps virus, Rubella virus, Varicella-zoster virus
|
negative-sense, single-stranded RNA
|
Live-attenuated
|
Phase 2
|
GlaxoSmithKline
|
2016
|
Canada
|
15 months - 6 years
|
NA
|
Subcutaneous
|
NA
|
Jeryl Lynn strain, Schwarz strain, RA 27/3 strain, OKA strain
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT00352898
|
https://clinicaltrials.gov/ct2/show/NCT00352898
|
https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-006065-14/DE
|
|
10312
|
RV3-BB
|
Rotavirus Infection
|
Gastrointestinal
|
Rotavirus
|
double stranded RNA
|
Live-attenuated
|
Phase 2
|
PT Biofarma
|
NA
|
Indonesia
|
0 - 5 days
|
3 doses regimen child schedule (0 to 5 days, 8 weeks, and 14 weeks of age or an infant schedule (8 weeks, 14 weeks, and 18 weeks of age)
|
Oral
|
NA
|
Three VP8 subunit proteins expressing P[4], P[6] and P[8] serotypes
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://preventrotavirus.org/wp-content/uploads/2019/05/ROTA-Brief2-ProductLandscape-SP-1-3.pdf
|
NA
|
|
10318
|
Covidful
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 3
|
Chinese Academy of Medical Sciences
|
2021
|
China
|
18 years and above
|
2 doses 2 weeks apart
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
Institute of Medical Biology
|
Brazil, Malaysia
|
IMBCAMS COVID-19 vaccine
|
NA
|
NCT04659239
|
https://clinicaltrials.gov/show/NCT04659239
|
https://clinicaltrials.gov/ct2/show/NCT05164731
|
|
10359
|
RSV F vaccine
|
Respiratory syncytial virus infection
|
Respiratory
|
Respiratory syncytial virus
|
negative-sense, single-stranded RNA
|
Live-attenuated
|
Phase 3
|
Novavax Inc.
|
2020
|
USA
|
18 - 40 years
|
2 doses 9 months apart
|
Intramuscular
|
Aluminum
|
RSV surface glycoprotein
|
NA
|
NA
|
Bill and Melinda Gates Foundation
|
NA
|
NA
|
NA
|
NCT02624947
|
https://clinicaltrials.gov/ct2/show/NCT02624947?recrs=bde&cond=Respiratory+Syncytial+Virus+%28RSV%29&phase=23&draw=2&rank=2
|
NA
|
|
10363
|
STAMARiL
|
Yellow fever
|
Hemorrhagic
|
Yellow fever virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 3
|
Sanofi Pasteur
|
NA
|
France
|
10 months
|
Single dose
|
Subcutaneous
|
NA
|
17D-204 strain of yellow fever virus
|
Produced in specified pathogen-free chick embryos
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.sanofipasteur.co.uk/-/media/ems/conditions/vaccines/brands/oneportal-ie/pdf/105_stamaril_mah_address_update_12_2017_uk.pdf
|
NA
|
|
10364
|
TAK-003
|
Dengue fever
|
Hemorrhagic
|
Dengue virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 3
|
Takeda Pharmaceutical Company Limited
|
NA
|
USA
|
4 - 16 years
|
NA
|
Subcutaneous
|
NA
|
Dengue virus serotypes (1, 2, 3 and 4)
|
Mammalian cell vero culture
|
NA
|
NA
|
NA
|
TDV
|
30684747
|
NA
|
https://www.sciencedirect.com/science/article/pii/S1201971219300402
|
NA
|
|
10365
|
TV-003/005
|
Dengue fever
|
Hemorrhagic
|
Dengue virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 3
|
Merck & Co. Inc.
|
NA
|
Brazil
|
2 - 59 years
|
NA
|
Subcutaneous
|
NA
|
Dengue virus serotypes (1, 2, 3 and 4)
|
Mammalian cell vero culture
|
NA
|
National Institute of Allergy and Infectious Diseases
|
NA
|
TetraVax-DV
|
30684747
|
NCT02406729
|
https://www.sciencedirect.com/science/article/pii/S1201971219300402
|
https://clinicaltrials.gov/ct2/show/NCT02406729
|
|
10370
|
JE-VAX
|
Viral encephalitis
|
Neurologic
|
West Nile virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 3
|
Research Foundation for Microbial Diseases of Osaka University
|
NA
|
China
|
NA
|
NA
|
Subcutaneous
|
NA
|
Nakayama-NIH/Beijing-1(P1) strain
|
Mouse brain based
|
NA
|
NA
|
Asia
|
SA 14-14-2 vaccine
|
24161909
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185882/
|
NA
|
|
10374
|
MRVAC
|
Measles, Rubella
|
Exanthous
|
Morbillivirus, Rubella virus
|
negative-sense, single-stranded RNA
|
Live-attenuated
|
Phase 3
|
Center for Research and Production of Vaccines and Biologicals
|
2018
|
Vietnam
|
1 - 45 years
|
NA
|
Subcutaneous
|
NA
|
Strain AIK-C measles virus clone with Takahashi rubella virus
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT03713359
|
https://clinicaltrials.gov/ct2/show/NCT03713359?recrs=abde&cond=measles+vaccines&phase=123&draw=2&rank=54
|
NA
|
|
10377
|
Lamb rotavirus
|
Rotavirus Infection
|
Gastrointestinal
|
Rotavirus
|
double stranded RNA
|
Live-attenuated
|
Phase 4
|
Lanzhou Biologicals
|
2000
|
China
|
6 months - 35 months
|
NA
|
Oral
|
NA
|
Single strain of rotavirus found in lamb (G10P)
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.who.int/immunization/research/meetings_workshops/11_Cassels_Rotavirus_PDVAC_2019.pdf?ua=1
|
https://preventrotavirus.org/wp-content/uploads/2019/05/ROTA-Brief2-ProductLandscape-SP-1-3.pdf
|
|
10378
|
ROTAVIN-M1
|
Rotavirus Infection
|
Gastrointestinal
|
Rotavirus
|
double stranded RNA
|
Live-attenuated
|
Phase 4
|
Polyvac, Center for Research and Production of Vaccines
|
NA
|
Vietnam
|
6 months - 8 months
|
NA
|
Oral
|
NA
|
Human rotavirus strain (G1P)
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.who.int/immunization/research/meetings_workshops/11_Cassels_Rotavirus_PDVAC_2019.pdf?ua=1
|
https://preventrotavirus.org/wp-content/uploads/2019/05/ROTA-Brief2-ProductLandscape-SP-1-3.pdf
|
|
10382
|
EXD-12
|
Genital Herpes
|
Cutaneous
|
Herpes simplex virus
|
double stranded DNA
|
Live-attenuated
|
Preclinical
|
Excell Biotech
|
2018
|
USA
|
14 - 49 years
|
NA
|
NA
|
NA
|
Herpes simplex virus 2 glycoprotein D (gD-2)
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.precisionvaccinations.com/vaccines/herpes-vaccine-candidates
|
NA
|
|
10384
|
RVx201
|
Genital Herpes
|
Cutaneous
|
Herpes simplex virus
|
double stranded DNA
|
Live-attenuated
|
Preclinical
|
Rational Vaccines Inc.
|
2021
|
UK
|
NA
|
NA
|
NA
|
NA
|
HSV-2 infected cell protein
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.precisionvaccinations.com/vaccines/herpes-vaccine-candidates
|
NA
|
|
10385
|
DeltaC-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
Subcutaneous
|
NA
|
Capsid deletion
|
NA
|
NA
|
NA
|
NA
|
NA
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10386
|
Stop CHIKV SuperStop CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
Footpad injection
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
31921059
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/
|
NA
|
|
10387
|
DRDE-06
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
3 doses
|
NA
|
NA
|
NA
|
Formalin inactivated produced in vero cells
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10391
|
Chimeric alphavirus
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
NA
|
NA
|
CHIKV structural proteins
|
Recombinant alphavirus (EEEV, VEEV, SINV) with CHIKV structural proteins
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10392
|
CHIKV/IRES
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
NA
|
NA
|
CHIKV structural proteins
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10393
|
VSV-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
Single dose
|
NA
|
NA
|
CHIKV structural proteins
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://academic.oup.com/jid/article/214/suppl_5/S488/2632628
|
NA
|
|
10399
|
LR-E2-E79 K
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
Clinical strain LR attenuated by mutations in heparin sulfate binding domains
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10400
|
CHIKV TM17-2
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
Clinical strain attenuated by mutations in E2 transmembrane domain
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10401
|
CHIKV/IRES
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|